 Shares of Aimmune Therapeutics Inc NASDAQ:AIMT have been assigned an average rating of Buy from the fourteen brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating on the company. The average ... 